Investors should review the full proxy statement to understand the qualifications of director nominees and the details of the stock award plan before voting. The shareholder proposal on board independence may be of particular interest to governance-focused investors.
BMY drugs
BMY drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 26 $59.39entry
- T+1 · 8mo ago −1.55%α +0.13% · $58.47
- T+5 · 8mo ago +0.32%α −1.31% · $59.58
- T+20 · 7mo ago −1.15%α −11.81% · $58.71
- T+60 · 5mo ago −7.89%α −23.28% · $54.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bristol-Myers Squibb Co filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting. The filing outlines proposals for shareholder vote, including the election of 11 directors, an advisory vote on executive compensation, approval of a new stock award plan, ratification of the auditor, and a shareholder proposal to make the board chair independent.
Key Facts
- Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting
- Proposals include election of 11 director nominees
- Advisory vote on executive compensation
- Vote to approve the 2026 Stock Award and Incentive Plan
- Ratification of the appointment of the independent auditor
- Shareholder proposal to adopt a board policy that the chairperson be independent
- Board recommends voting FOR all proposals except the shareholder proposal, which it recommends AGAINST
Financial Impact
No direct financial impact from this proxy filing. The proposals relate to corporate governance and executive compensation, not financial transactions.
Risk Factors
- Shareholder proposal may not pass if board recommendation is followed
- Potential for activist investor campaigns if governance concerns persist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-011110 |
| Document: 0001140361-26-011110-index-headers.html | 0001140361-26-011110 |
| Document: 0001140361-26-011110-index.html | 0001140361-26-011110 |
| Document: 0001140361-26-011110.txt | 0001140361-26-011110 |
Track record
9 reports on BMY
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +6.33% at T+20 after the Aug 5, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $62.14 to $62.14 Now $62.93 +1.27% · 0.00% −2.37% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $61.39 to $62.48 Now $62.93 +2.51% ▲ +1.78% +3.55% vs SPY
- Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $61.48 to $61.61 Now $62.93 +2.36% ▲ +0.21% −0.50% vs SPY
- Oct 5, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Aug 17, 202613w ago Institutional Cluster Bullish 6/10 Entry $64.63 to $66.05 Now $62.93 −2.63% ▲ +2.20% +2.87% vs SPY
- Aug 5, 202614w ago ANALYST-UPGRADE Bullish 4/10 Entry $63.63 to $64.15 Now $62.93 −1.10% ▲ +0.82% +0.98% vs SPY
- Jul 30, 202615w ago 8-K Bullish 7/10 Entry $64.86 to $65.31 Now $62.93 −2.98% ▲ +0.69% −0.01% vs SPY
- Mar 25, 202633w ago DEFA14A Neutral 3/10 Viewing Entry $59.39 to $58.47 Now $62.93 +5.97% ▼ −1.55% +0.13% vs SPY
- Feb 26, 202637w ago Court Ruling Neutral 3/10 Entry $62.37 to $62.34 Now $62.93 +0.90% ▼ −0.05% −0.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers